[1]
|
E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, et al., “Global Strategy for Asthma Management and Prevention: GINA Executive Summary,” European Respiratory Journal, Vol. 31, No. 1, 2008, pp. 143-178. http://dx.doi.org/10.1183/09031936.00138707
|
[2]
|
M. Cazzola and M. Molimard, “The Scientific Rationale for Combining Long-Acting β2-Agonists and Muscarinic Antagonists in COPD,” Pulmonary Pharmacology & Therapeutics, Vol. 23, No. 4, 2010, pp. 257-267. http://dx.doi.org/10.1016/j.pupt.2010.03.003
|
[3]
|
V. A. Cullum, J. B. Farmer, D. Jack and G. P. Levy, “Salbutamol: A New, Selective β-Adrenoceptive Receptor Stimulant,” British Journal of Pharmacology, Vol. 35, No. 1, 1969, pp. 141-151. http://dx.doi.org/10.1111/j.1476-5381.1969.tb07975.x
|
[4]
|
G. P. Anderson, “Formoterol: Pharmacology, Molecular Basis of Agonism, and Mechanism of Long Duration of a Highly Potent and Selective β2-Adrenoceptor Agonist Bronchodilator,” Life Sciences, Vol. 52, No. 26, 1993, pp. 2145-2160. http://dx.doi.org/10.1016/0024-3205(93)90729-M
|
[5]
|
M. Johnson, P. R. Butchers, R. A. Coleman, A. T. Nials, P. Strong, et al., “The Pharmacology of Salmeterol,” Life Sciences, Vol. 52, No. 26, 1993, pp. 2131-2143. http://dx.doi.org/10.1016/0024-3205(93)90728-L
|
[6]
|
M. Cazzola, L. Calzetta and M. G. Matera, “β2-Adrenoceptor Agonists: Current and Future Direction,” British Journal of Pharmacology, Vol. 163, No. 1, 2011, pp. 4-17. http://dx.doi.org/10.1111/j.1476-5381.2011.01216.x
|
[7]
|
G. P. Anderson, A. Lindén and K. F. Rabe, “Why Are Long-Acting Beta-Adrenoceptor Agonists Long-Acting?” European Respiratory Journal, Vol. 7, No. 3, 1994, pp. 569-578. http://dx.doi.org/10.1183/09031936.94.07030569
|
[8]
|
R. A. Coleman, M. Johnson, A. T. Nials and C. J. Vardey, “Exosites: Their Current Status, and Their Relevance to the Duration of Action of Long-Acting β2-Adrenoceptor Agonists,” Trends in Pharmacological Sciences, Vol. 17, No. 9, 1996, pp. 324-330. http://dx.doi.org/10.1016/0165-6147(96)10040-7
|
[9]
|
P. Casarosa, I. Kollak, T. Kiechle, A. Ostermann, A. Schnapp, et al., “Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol,” Journal of Pharmacology and Experimental Therapeutics, Vol. 337, No. 3, 2011, pp. 600-609. http://dx.doi.org/10.1124/jpet.111.179259
|
[10]
|
R. M. Wallace and J. M. Young, “Temperature Dependence of the Binding of [3H]Mepyramine and Related Compounds to the Histamine H1 Receptor,” Molecular Pharmacology, Vol. 23, No. 1, 1983, pp. 60-66.
|
[11]
|
A. Szczuka, M. Wennerberg, A. Packeu and G. Vauquelin, “Molecular Mechanisms for the Persistent Bronchodilatory Effect of the β2-Adrenoceptor Agonist Salmeterol,” British Journal of Pharmacology, Vol. 158, No. 1, 2009, pp. 183-194. http://dx.doi.org/10.1111/j.1476-5381.2009.00296.x
|
[12]
|
J. C. W. Mak, B. Grandordy and P. J. Barnes, “High Affinity [3H]Formoterol Binding Sites in Lung: Characterization and Autoradiographic,” European Journal of Pharmacology: Molecular Pharmacology, Vol. 269, No. 1, 1994, pp. 35-41. http://dx.doi.org/10.1016/0922-4106(94)90023-X
|
[13]
|
R. J. Slack, V. J. Barrett, V. S. Morrison, R. G. Sturton, A. J. Emmons, et al., “In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2 Adrenoceptor Agonist with 24-Hour Duration of Action,” Journal of Pharmacology and Experimental Therapeutics, Vol. 344, No. 1, 2013, pp. 218-230. http://dx.doi.org/10.1124/jpet.112.198481
|
[14]
|
P. A. Procopiou, V. J. Barrett, N. J. Bevan, K. Biggadike, P. C. Box, et al., “Synthesis and Structure-Activity Relationships of Long-Acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach,” Journal of Medicinal Chemistry, Vol. 53, No. 11, 2010, pp. 4522-4530. http://dx.doi.org/10.1021/jm100326d
|
[15]
|
P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, et al., “Measurement of Protein Using Bicinchoninic Acid,” Analytical Biochemistry, Vol. 150, No. 1, 1985, pp. 76-85. http://dx.doi.org/10.1016/0003-2697(85)90442-7
|
[16]
|
J. G. Baker, “The Selectivity of β-Adrenoceptor Antagonists at the Human β1, β2 and β3 Adrenoceptors,” British Journal of Pharmacology, Vol. 144, No. 3, 2005, pp. 317-322. http://dx.doi.org/10.1038/sj.bjp.0706048
|
[17]
|
S. A. Holm, “A Simple Sequentially Rejective Multiple test Procedure,” Scandinavian Journal of Statistics, Vol. 6, No. 2, 1979, pp. 65-70.
|